Hexapeptide-9: complete guide

Hexapeptide-9, sold as Collaxyl, is a six-amino-acid synthetic cosmetic peptide. This guide covers its structure, the research on it and on a cyclized form, and its status.

Complete guide5 min read

Key takeaway

PubChem lists hexapeptide-9 at 582.6 g/mol, with the formula C24H38N8O9. The EU CosIng database lists one cosmetic function: skin conditioning. The largest human trial we found, with 96 participants, tested a cyclized version, not hexapeptide-9 itself.

At a glance

Article typeComplete guide
Regulatory statusCosmetic / topical“Hexapeptide-9 is a cosmetic ingredient, not an FDA-approved drug.” (this article)
ClassSkin & cosmetic
Body systemsSkin & connective tissue
Studies cited3 in this article · 3 across 1 article on Hexapeptide-9
Related productsCopper peptides and melanocortin fragments

Hexapeptide-9 is a synthetic six-amino-acid peptide, Gly-Pro-Gln-Gly-Pro-Gln, used as a cosmetic ingredient and sold by Ashland as Collaxyl. This guide covers its structure, the research on it and on a ring-shaped version, and its regulatory status. Sources were checked on November 17, 2026.

Quick answer: Hexapeptide-9 is a lab-made peptide built from glycine, proline and glutamine, described by researchers as a collagen peptide. Ashland sells it as Collaxyl. Most of its evidence is manufacturer data, a skin-delivery study and a trial of a modified ring form. It is a cosmetic ingredient, not a drug, and we found no Cosmetic Ingredient Review safety assessment for it.

Vitrapep does not sell hexapeptide-9; this page is a reference summary of published research and regulatory information.

What is hexapeptide-9?

Hexapeptide-9 is an INCI name, the standard name used on cosmetic ingredient lists. CosIng, the European Commission’s cosmetic ingredient database, describes it as “a synthetic peptide containing Glutamine, Glycine and Proline residues” (CosIng, 2026). “Hexa” means six.

PubChem gives the sequence as Gly-Pro-Gln-Gly-Pro-Gln, a repeated three-unit pattern. It lists the formula as C24H38N8O9 and the molecular weight as 582.6 g/mol (PubChem CID 16129319). Its INCI name carries no acetyl or palmitoyl prefix, so it has no added cap or fatty-acid tail. Our peptide primer covers the basics.

A 2025 trial report calls hexapeptide-9 “a collagen peptide” (Chang et al., 2025). Collagen is the main structural protein of skin. See our collagen peptides explainer for how that term is used.

Ashland sells Collaxyl IS biofunctional, with an INCI listing of water, butylene glycol and hexapeptide-9 (Ashland). PubChem also lists Collaxyl IS as a synonym.

Table 1

Hexapeptide-9: key facts

Fact Detail
INCI name Hexapeptide-9
Structure type Linear synthetic peptide; six amino acids; no acyl group
Sequence Gly-Pro-Gln-Gly-Pro-Gln (GPQGPQ)
Molecular formula C24H38N8O9
Molecular weight 582.6 g/mol
Main cosmetic function (CosIng) Skin conditioning
Trade name(s) Collaxyl IS; Collaxyl ng (Ashland)

How does hexapeptide-9 work?

We found no peer-reviewed study that pins down a mechanism for hexapeptide-9 alone. Ashland’s product page claims the ingredient “enhances epidermal renewal (ex vivo)” (Ashland). We could not find the underlying data.

One independent study proposed a pathway. Working with hexapeptide-9 and a skin-delivery aid, Wang and colleagues linked its effects in their models to PPAR signaling. They reported lower UV-induced oxidative stress, inflammation and collagen breakdown (Wang et al., 2025). PPARs are receptor proteins that control sets of genes. Because the study paired the peptide with an enhancer, it does not show the peptide’s action alone.

What is hexapeptide-9 used for?

CosIng lists one cosmetic function for hexapeptide-9: skin conditioning. A skin-conditioning agent helps keep skin in good condition. The CosIng record links no annex of the EU Cosmetics Regulation and no scientific committee opinion to this ingredient.

Ashland says Collaxyl “rapidly decreases the appearance of skin wrinkles (in vivo).” That is a manufacturer claim about appearance, not an FDA finding. A related ingredient, caffeoyl hexapeptide-9, adds a caffeoyl group to the same sequence (Bjerke et al., 2026). For the wider field, see our peptides in skincare overview.

What does the research show?

Wang 2025 (lab, animal and human work). Researchers paired hexapeptide-9 with GALA, an ionic liquid made from GABA and lactic acid. After 12 hours, the amount passing through skin rose 4.79-fold and the amount kept in skin rose 7.89-fold, compared with no enhancer. The abstract gives no clinical sample size. Some authors work for Bloomage Biotechnology, and Chinese science agencies funded the work (Wang et al., 2025).

Chang 2025 (human randomized trial of a cyclized form). This team joined the head and tail of hexapeptide-9 with an amide bond to make a ring, called CHP-9. Ninety-six Asian participants were randomized to a CHP-9 serum, a retinol serum or a vehicle serum, and 91 completed 56 days. The authors reported larger reductions in forehead and crow’s feet wrinkle measures with CHP-9 than with retinol, on most outcomes.

The trial reported no treatment-related adverse events. The authors work for two Shanghai cosmetics and biotech companies and report no specific funding (Chang et al., 2025). CHP-9 is a different molecule from linear hexapeptide-9, so these results do not transfer directly.

Manufacturer data. Ashland’s in vivo and ex vivo claims are not, as far as we found, published in peer-reviewed form.

What safety data exist?

We found no Cosmetic Ingredient Review (CIR) safety assessment for hexapeptide-9. CIR’s quick reference table, September 2020 edition, does not list it (CIR, 2020). It lists a different peptide, hexapeptide-12, which CIR found safe as used. Searches of the CIR website and PubMed found no later hexapeptide-9 report.

A 2026 framework paper, mostly by Procter & Gamble scientists, screened caffeoyl hexapeptide-9 with computer tools. It found likeness to a database peptide tagged as anti-aging, and only weak likeness to an uncommon cattle allergen (Bjerke et al., 2026). The Chang trial of the cyclized form reported no treatment-related adverse events.

What is hexapeptide-9’s regulatory status, and how is it used in research?

Hexapeptide-9 is a cosmetic ingredient, not an FDA-approved drug. FDA states that cosmetic products and ingredients, except color additives, “do not need FDA premarket approval” (FDA, 2025). Products meant to treat or prevent disease are drugs (FDA, 2024).

Congress enacted the Modernization of Cosmetics Regulation Act of 2022 (MoCRA) on December 29, 2022 (FDA, 2026). It requires facility registration, product listing, serious adverse event reports within 15 business days, and safety records (FDA MoCRA page).

In research, hexapeptide-9 serves as a model collagen-type peptide for skin-delivery work, as in the Wang study. It is also the parent sequence for modified forms such as CHP-9 and caffeoyl hexapeptide-9.

Frequently asked questions about hexapeptide-9

Is hexapeptide-9 the same as Collaxyl?

Collaxyl is Ashland’s trade name for an ingredient solution whose INCI listing includes hexapeptide-9. PubChem also lists Collaxyl IS as a synonym.

Is hexapeptide-9 a peptide?

Yes. It is six amino acids, Gly-Pro-Gln-Gly-Pro-Gln, joined by peptide bonds.

Is cyclized hexapeptide-9 the same thing?

No. CHP-9 joins both ends of the chain into a ring. It is a modified molecule tested in a separate trial.

Is hexapeptide-9 FDA-approved?

No. It is a cosmetic ingredient. US cosmetic ingredients, other than color additives, do not need FDA premarket approval.

Is hexapeptide-9 the same as hexapeptide-12?

No. They are separate INCI entries. CIR has assessed hexapeptide-12 but, in the sources we checked, not hexapeptide-9.

What to know now

  • Identity: Gly-Pro-Gln-Gly-Pro-Gln; trade name Collaxyl; 582.6 g/mol.
  • CosIng function: skin conditioning.
  • Evidence: a skin-delivery study with an enhancer, and a 96-person trial of a cyclized form.
  • Manufacturer claims: appearance and epidermal renewal claims not found in peer-reviewed form.
  • Safety: no CIR or SCCS assessment found.
  • Status: cosmetic ingredient; not an FDA-approved drug.

What we’re watching

FDA’s ongoing MoCRA rollout, tracked on its MoCRA page. Any CIR review of hexapeptide-9, which would appear on cir-safety.org. Related guides: Matrixyl, palmitoyl hexapeptide-12 and tripeptide-10 citrulline.

More for skin & connective tissue

All 23 compounds for skin & connective tissue

Sources: European Commission 2026, CosIng: HEXAPEPTIDE-9; National Center for Biotechnology Information 2026, PubChem compound summary for CID 16129319, hexapeptide-9; Ashland. Collaxyl IS biofunctional (product page). Retrieved November 17, Collaxyl IS biofunctional; Chang 2025, Journal of Cosmetic Dermatology, 24; Wang 2025, Materials Today Bio, 31; Bjerke 2026, Current Research in Toxicology, 10; Cosmetic Ingredient Review 2020, Quick reference table; U.S. Food and Drug Administration 2025, FDA authority over cosmetics: How cosmetics are not FDA-approved, but are FDA-regulated; U.S. Food and Drug Administration 2024, Is it a cosmetic, a drug, or both? (Or is it soap?); U.S. Food and Drug Administration 2026, Modernization of Cosmetics Regulation Act of 2022 (MoCRA); Kozlowski 2026, How FDA is implementing landmark cosmetics legislation to positively impact public health. All 11 citations

Back to the research library

References

  1. European Commission. (2026). CosIng: HEXAPEPTIDE-9 (substance ID 56433). Retrieved November 17, 2026, from https://ec.europa.eu/growth/tools-databases/cosing/details/56433
  2. National Center for Biotechnology Information. (2026). PubChem compound summary for CID 16129319, hexapeptide-9. Retrieved November 17, 2026, from https://pubchem.ncbi.nlm.nih.gov/compound/16129319
  3. Ashland. Collaxyl IS biofunctional (product page). Retrieved November 17, 2026, from https://www.ashland.com/industries/personal-and-home-care/skin-and-sun-care/collaxyl-is-biofunctional
  4. Chang, H., et al. (2025). Novel cyclized hexapeptide-9 outperforms retinol against skin aging: A randomized, double-blinded, active- and vehicle-controlled clinical trial. Journal of Cosmetic Dermatology, 24(7), e70290. https://doi.org/10.1111/jocd.70290
  5. Wang, M., et al. (2025). Pioneering ionic liquids in neuro-soothing: Enhanced transdermal delivery of collagen peptides and their synergistic anti-aging functions. Materials Today Bio, 31, 101527. https://doi.org/10.1016/j.mtbio.2025.101527
  6. Bjerke, D. L., et al. (2026). A framework for the safety evaluation of peptides in cosmetics. Current Research in Toxicology, 10, 100291. https://doi.org/10.1016/j.crtox.2026.100291
  7. Cosmetic Ingredient Review. (2020). Quick reference table (September 2020). Retrieved November 17, 2026, from https://www.cir-safety.org/sites/default/files/qrt-fix_0.pdf
  8. U.S. Food and Drug Administration. (2025). FDA authority over cosmetics: How cosmetics are not FDA-approved, but are FDA-regulated (content current as of 11/18/2025). Retrieved November 17, 2026, from https://www.fda.gov/cosmetics/cosmetics-laws-regulations/fda-authority-over-cosmetics-how-cosmetics-are-not-fda-approved-are-fda-regulated
  9. U.S. Food and Drug Administration. (2024). Is it a cosmetic, a drug, or both? (Or is it soap?) (content current as of 09/11/2024). Retrieved November 17, 2026, from https://www.fda.gov/cosmetics/cosmetics-laws-regulations/it-cosmetic-drug-or-both-or-it-soap
  10. U.S. Food and Drug Administration. (2026). Modernization of Cosmetics Regulation Act of 2022 (MoCRA) (content current as of 10/29/2026). Retrieved November 17, 2026, from https://www.fda.gov/cosmetics/cosmetics-laws-regulations/modernization-cosmetics-regulation-act-2022-mocra
  11. Kozlowski, S. (2026). How FDA is implementing landmark cosmetics legislation to positively impact public health (FDA Voices; content current as of 05/04/2026). U.S. Food and Drug Administration. https://www.fda.gov/news-events/fda-voices/how-fda-implementing-landmark-cosmetics-legislation-positively-impact-public-health